Journal: International Journal of Biological Sciences
Article Title: Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor
doi: 10.7150/ijbs.130389
Figure Lengend Snippet: Clonotype-resolved single-cell TCR analysis identifies tumor-reactive TCR sequence from CD39⁺CD8⁺ TILs. (A) Distribution of TCR clonotypes from MB49 tumor. (B) Stacked chart shows TCR clone-size distribution of CD39 +/- CD8 + T cells population. (C) Tree maps of TCR clonotypes in CD39 +/- CD8 + TIL population. (D) Co-expression of CD39 and N4 tetramer among CD8 + TILs in MB49-OVA tumor. (E) mRNA expression levels of Tnf , Ifng , Gzma , Gzmk , Prf1 and Nkg7 in the dominant TCR clonotype of CD39 + CD8 + TILs and the top 5 TCR clonotypes from CD39 - CD8 + TILs. (F) Scheme summarizes the activation and cytotoxicity assay of tumor reactive TCR. (G-H) Expression of CD69 on TCR-Jurkat cells after co-culture with MB49 tumor cells. (I) Viral infection efficiency of TCR-T cells. (J) Representative microscopy image after 24 hours co-culture of TCR-T cells with MB49 tumor cells. (K) Tumor cell killing by TCR-T cells in co-culture with MB49 cells. (L) TCR-Jurkat co-cultured with tumor cells of different MHC background, including CT26 (H-2K d ) or UMUC3 (HLA-A*02). (M) TCR-Jurkat co-cultured with normal renal cells. ns, P > 0.05, *** P < 0.001.
Article Snippet: For double IHC staining, anti-human CD8 monoclonal antibody (Proteintech, cat#66868-1-Ig) and anti-human CD39 polyclonal antibody (Proteintech, cat#14211-1-AP) were used for IHC staining.
Techniques: Single Cell, Sequencing, Expressing, Activation Assay, Cytotoxicity Assay, Co-Culture Assay, Infection, Microscopy, Cell Culture